Key Takeaways Oppenheimer analysts on Thursday said that given this week's tariff news, they prefer defensive consumer stocks ...

Nolan is writing the script and producing the film alongside his wife, Emma Thomas, through their production company, Syncopy ...

Despite recent market turbulence, Oppenheimer Asset Management expressed continued optimism about equities. Learn more here.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...

As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...

Oppenheimer raised the firm’s price target on AT&T to $32 from $27 and keeps an Outperform rating on the shares. The firm cites better free ...

Joshua Oppenheimer made his name directing two disturbing documentaries, The Act of Killing (2012) and The Look of Silence ...

Yet, MAD still dominates countries’ nuclear thinking. Opinion: Our nuclear weapons are much more powerful than Oppenheimer's atomic bomb At a time of profound global changes and instability ...

Oppenheimer maintained its Outperform rating on AppLovin (APP) while highlighting key points for the company from the ...

A popular theory frequently utilized by technical analysts suggests U.S. stocks could be headed for one last leg higher over ...

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares ...